These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 31611133)

  • 21. Macrophagic myofasciitis associated with vaccine-derived aluminium.
    Shingde M; Hughes J; Boadle R; Wills EJ; Pamphlett R
    Med J Aust; 2005 Aug; 183(3):145-6. PubMed ID: 16053418
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hypersensitivity reactions to vaccine constituents: a case series and review of the literature.
    Leventhal JS; Berger EM; Brauer JA; Cohen DE
    Dermatitis; 2012; 23(3):102-9. PubMed ID: 22653170
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Influence of aluminum adjuvant to experimental rabies vaccine].
    Lin H; Perrin P
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1999 Jun; 13(2):133-5. PubMed ID: 12569779
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Addressing parents' concerns: do vaccines contain harmful preservatives, adjuvants, additives, or residuals?
    Offit PA; Jew RK
    Pediatrics; 2003 Dec; 112(6 Pt 1):1394-7. PubMed ID: 14654615
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PERTUSSIS VACCINE TESTING FOR FREEDOM-FROM-TOXICITY.
    PITTMAN M; COX CB
    Appl Microbiol; 1965 May; 13(3):447-56. PubMed ID: 14325286
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gulf war illness, post-HPV vaccination syndrome, and Macrophagic Myofasciitis. Similar disabling conditions possibly linked to vaccine-induced autoimmune dysautonomia.
    Martinez-Lavin M; Tejada-Ruiz M
    Autoimmun Rev; 2020 Sep; 19(9):102603. PubMed ID: 32659478
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aluminium overload after 5 years in skin biopsy following post-vaccination with subcutaneous pseudolymphoma.
    Guillard O; Fauconneau B; Pineau A; Marrauld A; Bellocq JP; Chenard MP
    J Trace Elem Med Biol; 2012 Oct; 26(4):291-3. PubMed ID: 22425036
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Macrophagic myofasciitis: an infantile Italian case.
    Di Muzio A; Capasso M; Verrotti A; Trotta D; Lupo S; Pappalepore N; Manzoli C; Chiarelli F; Uncini A
    Neuromuscul Disord; 2004 Feb; 14(2):175-7. PubMed ID: 14733966
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glassy-state stabilization of a dominant negative inhibitor anthrax vaccine containing aluminum hydroxide and glycopyranoside lipid A adjuvants.
    Hassett KJ; Vance DJ; Jain NK; Sahni N; Rabia LA; Cousins MC; Joshi S; Volkin DB; Middaugh CR; Mantis NJ; Carpenter JF; Randolph TW
    J Pharm Sci; 2015 Feb; 104(2):627-39. PubMed ID: 25581103
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aluminum in vaccines: Does it create a safety problem?
    Principi N; Esposito S
    Vaccine; 2018 Sep; 36(39):5825-5831. PubMed ID: 30139653
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Updated aluminum pharmacokinetics following infant exposures through diet and vaccination.
    Mitkus RJ; King DB; Hess MA; Forshee RA; Walderhaug MO
    Vaccine; 2011 Nov; 29(51):9538-43. PubMed ID: 22001122
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of a high-throughput screening platform to study the adsorption of antigens onto aluminum-containing adjuvants.
    Jully V; Moniotte N; Mathot F; Lemoine D; Préat V
    J Pharm Sci; 2015 Feb; 104(2):557-65. PubMed ID: 25470455
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Methods to Prepare Aluminum Salt-Adjuvanted Vaccines.
    Thakkar SG; Cui Z
    Methods Mol Biol; 2017; 1494():181-199. PubMed ID: 27718194
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aluminum Effects in Infants and Children.
    Corkins MR;
    Pediatrics; 2019 Dec; 144(6):. PubMed ID: 31767714
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of Formulation and Suspension Properties on Redispersion of Aluminum-Adjuvanted Vaccines.
    Langford A; Horwitz T; Adu-Gyamfi E; Wiley C; Holding E; Zimmermann D; Ignatius AA; Ohtake S
    J Pharm Sci; 2020 Apr; 109(4):1460-1466. PubMed ID: 31930978
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Towards toxicokinetic modelling of aluminium exposure from adjuvants in medicinal products.
    Weisser K; Stübler S; Matheis W; Huisinga W
    Regul Toxicol Pharmacol; 2017 Aug; 88():310-321. PubMed ID: 28237896
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative Safety of Vaccine Adjuvants: A Summary of Current Evidence and Future Needs.
    Petrovsky N
    Drug Saf; 2015 Nov; 38(11):1059-74. PubMed ID: 26446142
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aluminum vaccine adjuvants: are they safe?
    Tomljenovic L; Shaw CA
    Curr Med Chem; 2011; 18(17):2630-7. PubMed ID: 21568886
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) 2013: Unveiling the pathogenic, clinical and diagnostic aspects.
    Perricone C; Colafrancesco S; Mazor RD; Soriano A; Agmon-Levin N; Shoenfeld Y
    J Autoimmun; 2013 Dec; 47():1-16. PubMed ID: 24238833
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aluminium-adjuvanted vaccines--a review of the current state of knowledge.
    Gołoś A; Lutyńska A
    Przegl Epidemiol; 2015; 69(4):731-4, 871-4. PubMed ID: 27139352
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.